Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Australia
/
Healthcare
/
PolyNovo
PNV
PolyNovo
Global Cost Pressures And Regulatory Risks Will Cripple Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
01 Aug 25
Updated
01 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
AU$1.15
4.3% undervalued
intrinsic discount
01 Aug
AU$1.10
Loading
1Y
-57.9%
7D
-6.8%
Author's Valuation
AU$1.2
4.3% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
AU$1.2
4.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-6m
202m
2014
2017
2020
2023
2025
2026
2028
Revenue AU$201.7m
Earnings AU$30.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.67%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.15%
Calculation
AU$30.81m
Earnings '28
x
31.70x
PE Ratio '28
=
AU$976.79m
Market Cap '28
AU$976.79m
Market Cap '28
/
692.68m
No. shares '28
=
AU$1.41
Share Price '28
AU$1.41
Share Price '28
Discounted to 2025 @ 7.07% p.a.
=
AU$1.15
Fair Value '25
